Ambraksol

Product Description

To liquify bronchi secretion in case of acute and chronic pulmonary diseases, (e.g., bronchial asthma, bronchitis, bronchiectasia) when sputum formation and elimination disorders occur.

Product Mechanism of Action

The drug’s active substance ambroxol (benzylamine derivative, bromhexine metabolite) is a direct action broncho-secretolytic or mucolytic agent with a strong expectorant effect. Ambroxol has secretolytic and secretomotoric effect. Ambroxol stimulates lysosomal enzymes release and hydrolytic enzymes activity in mucolytic cells that contribute to polysaccharide and protein cleavage in bronchial sputum. Ambroxol promote bronchial mucous glands serosa cells activity, thereby normalizing the serosa and mucous component of the relationship of bronchial secretions. As a result, sputum viscosity decreases. Ambroxol increases the amount of surfactant in the lungs, stimulating the synthesis and secretion in alveolar pneumocytes, promotes mucociliar transport facilitating the elimination of sputum from the bronchi.

Dosage

Ambroksol 30 mg tablets are administered after meals with a glass of warm liquid. Liquid promotes Ambroksol activity. The drug should not be used before bedtime.
Adults and children over 12 years: dose is 30 mg thrice daily during 2-3 days, then – 30 mg twice daily. If necessary the dose may be increased till 60 mg 2 times daily. Maximal daily dose is
180 mg.
Children from 6 till 12 years: dose is 15 mg 2-3 times daily.
Children younger than 6 years – Ambroksol 30 mg tablets are not suitable due to the high dose of active substance in one tablet.
In case of renal and/or liver diseases Ambroksol 30 mg tablets can be used only under doctor’s control. In these cases the dose is decreased or the interval between the intakes of the drug is increased (see paragraph 4.4. Special warnings and precautions for use).
Duration of administration is determined individually and it can continue 4 till 14 days.